Skip to Main Content

Try STAT+ TODAY

Pharma

Taking stock of the drug industry, from the lab to the medicine chest. For a weekly update, sign up for our free Pharmalot newsletter. And subscribe to STAT+ for exclusive coverage and analysis of the pharma industry — from drug pipelines to boardroom shakeups.

Morning Rounds Newsletter

Insurance Bob Herman

STAT Plus: CVS warns PBM reforms ‘could lead to higher costs’

A top executive at CVS Health said the company would find ways to maintain its level of PBM profits if Congress makes reforms.

Pharmalot Ed Silverman

STAT Plus: Sacklers win appeal that shields them from opioid lawsuits, clearing way for bankruptcy settlement

Pharma John Wilkerson

STAT Plus: Just how vulnerable is Medicare drug negotiation to legal challenges?

Pharma Damian Garde

STAT Plus: Novo says oral version of Ozempic leads to 15% weight loss

Pharmalot Andrew Joseph

STAT Plus: Pharmalittle: Appeals court rules Purdue can shield Sacklers from lawsuits; chemo shortage blamed on drugmakers’ lack of investment

All Coverage

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Pfizer touts study data for hemophilia drug; former Novartis execs cleared of bribery in Greece

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

advertisement

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: EMA urges revoking authorization for Novartis sickle cell drug; U.K. tries to placate pharma execs

First Opinion Gloria Coronado and Leslie Bienen

STAT Plus: An overlooked way to make participants in clinical trials look more like America

Pharma Adam Feuerstein

STAT Plus: Bristol drug reduces reliance on transfusions for people with chronic blood disorder

Pharmalot Ed Silverman

STAT Plus: Gilead and Teva defend antitrust claims that prices for HIV medicines were unfairly kept high

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: FDA approvals will stop if U.S. defaults on its debts; DEA failed to punish wholesaler blamed in opioid crisis

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Biden administration proposes yearly audit for costliest Medicaid drugs; few at high risk of HIV take prevention pills

Politics John Wilkerson

STAT Plus: Congress highlighted a chemo drug’s price to blast PBMs

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Pfizer and Novo disclose upbeat data on oral weight loss drugs; PBM trade group blasts House committee over hearing

D.C. Diagnosis Sarah Owermohle

FDA budget battles, prisons’ sobering Covid response & BIO’s CEO search is on

Pharmalot Ed Silverman

STAT Plus: Seagen criticized by shareholder advisory firm for ‘problematic’ executive compensation ahead of Pfizer acquisition

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Many employer health plans won’t pay for obesity drugs; FDA panel rejects Intercept NASH drug

Pharma Elaine Chen

STAT Plus: In early trial, drug appears to reduce harmful protein buildup in heart

Pharmalot Ed Silverman

STAT Plus: 1 in 5 primary endpoints changed in late-stage trials of cancer drugs already underway, study finds

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Health Elaine Chen

STAT Plus: Novo Nordisk pauses ads for weight loss drug Wegovy as it struggles to meet demand

Politics John Wilkerson

STAT Plus: FDA official offers insights into whether gene therapy makers could use common manufacturing process

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: AstraZeneca plans to ‘love’ China’s Communist Party; U.S. Supreme Court rules against Amgen in patent case

First Opinion Arthur L. Caplan

STAT Plus: How I helped Pfizer think through the ethics of Viagra 25 years ago

Health Jason Mast

STAT Plus: After new cluster, health officials warn mpox could resurge this summer

Pharmalot Ed Silverman

STAT Plus: Supreme Court rules against Amgen in closely watched case over scope of patent claims

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Appellate judges appear skeptical of FDA decisions on abortion pill; FTC widens probe into PBMs

Pharmalot Ed Silverman

STAT Plus: FTC widens probe into pharmacy benefit managers to include group purchasing organizations